Very low-dose lenalidomide therapy for elderly multiple myeloma patients.

Kentaro Minagawa, Hiroki Kawano, Takuma Suzuki, Tadahiro Inagaki, Minoru Kishi, Tamaki Hirata, Sachiko Kimura, Miho Takechi, Toru Koide, Masahide Iwai, Yoshio Katayama, Toshimitsu Matsui

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Lenalidomide treatment for refractory or relapsed multiple myeloma in elderly patients may be feasible in an outpatient setting. However, difficulties have been associated with the management of adverse effects. Therefore, a dose reduction in lenalidomide has been recommended in some cases. In this report, we encountered the successful treatment of myeloma in 6 elderly patients (aged above 70 years) with very low-dose lenalidomide (5 mg daily). Four patients exhibited more than a partial response with an 8.6 months median follow-up period, which was comparable with previous findings. The major adverse effect observed was infection, which occurred during the first several cycles. Others were less toxic, especially the absence of grade 3/4 toxicities for hematological adverse effects.Although a dose reduction in lenalidomide therapy for elderly patients is controversial, a very low dose could be safe and effective. Our group is currently conducting a multi-center prospective trial to evaluate the efficacy of low-dose lenalidomide therapy.

Original languageEnglish (US)
Pages (from-to)457-462
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume54
Issue number5
StatePublished - May 1 2013

Fingerprint

Multiple Myeloma
Therapeutics
Poisons
Outpatients
lenalidomide
Infection

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Minagawa, K., Kawano, H., Suzuki, T., Inagaki, T., Kishi, M., Hirata, T., ... Matsui, T. (2013). Very low-dose lenalidomide therapy for elderly multiple myeloma patients. [Rinshō ketsueki] The Japanese journal of clinical hematology, 54(5), 457-462.
Minagawa, Kentaro ; Kawano, Hiroki ; Suzuki, Takuma ; Inagaki, Tadahiro ; Kishi, Minoru ; Hirata, Tamaki ; Kimura, Sachiko ; Takechi, Miho ; Koide, Toru ; Iwai, Masahide ; Katayama, Yoshio ; Matsui, Toshimitsu. / Very low-dose lenalidomide therapy for elderly multiple myeloma patients. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2013 ; Vol. 54, No. 5. pp. 457-462.
@article{25a3149491b148889945fd911cded5a3,
title = "Very low-dose lenalidomide therapy for elderly multiple myeloma patients.",
abstract = "Lenalidomide treatment for refractory or relapsed multiple myeloma in elderly patients may be feasible in an outpatient setting. However, difficulties have been associated with the management of adverse effects. Therefore, a dose reduction in lenalidomide has been recommended in some cases. In this report, we encountered the successful treatment of myeloma in 6 elderly patients (aged above 70 years) with very low-dose lenalidomide (5 mg daily). Four patients exhibited more than a partial response with an 8.6 months median follow-up period, which was comparable with previous findings. The major adverse effect observed was infection, which occurred during the first several cycles. Others were less toxic, especially the absence of grade 3/4 toxicities for hematological adverse effects.Although a dose reduction in lenalidomide therapy for elderly patients is controversial, a very low dose could be safe and effective. Our group is currently conducting a multi-center prospective trial to evaluate the efficacy of low-dose lenalidomide therapy.",
author = "Kentaro Minagawa and Hiroki Kawano and Takuma Suzuki and Tadahiro Inagaki and Minoru Kishi and Tamaki Hirata and Sachiko Kimura and Miho Takechi and Toru Koide and Masahide Iwai and Yoshio Katayama and Toshimitsu Matsui",
year = "2013",
month = "5",
day = "1",
language = "English (US)",
volume = "54",
pages = "457--462",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "5",

}

Minagawa, K, Kawano, H, Suzuki, T, Inagaki, T, Kishi, M, Hirata, T, Kimura, S, Takechi, M, Koide, T, Iwai, M, Katayama, Y & Matsui, T 2013, 'Very low-dose lenalidomide therapy for elderly multiple myeloma patients.', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 54, no. 5, pp. 457-462.

Very low-dose lenalidomide therapy for elderly multiple myeloma patients. / Minagawa, Kentaro; Kawano, Hiroki; Suzuki, Takuma; Inagaki, Tadahiro; Kishi, Minoru; Hirata, Tamaki; Kimura, Sachiko; Takechi, Miho; Koide, Toru; Iwai, Masahide; Katayama, Yoshio; Matsui, Toshimitsu.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 54, No. 5, 01.05.2013, p. 457-462.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Very low-dose lenalidomide therapy for elderly multiple myeloma patients.

AU - Minagawa, Kentaro

AU - Kawano, Hiroki

AU - Suzuki, Takuma

AU - Inagaki, Tadahiro

AU - Kishi, Minoru

AU - Hirata, Tamaki

AU - Kimura, Sachiko

AU - Takechi, Miho

AU - Koide, Toru

AU - Iwai, Masahide

AU - Katayama, Yoshio

AU - Matsui, Toshimitsu

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Lenalidomide treatment for refractory or relapsed multiple myeloma in elderly patients may be feasible in an outpatient setting. However, difficulties have been associated with the management of adverse effects. Therefore, a dose reduction in lenalidomide has been recommended in some cases. In this report, we encountered the successful treatment of myeloma in 6 elderly patients (aged above 70 years) with very low-dose lenalidomide (5 mg daily). Four patients exhibited more than a partial response with an 8.6 months median follow-up period, which was comparable with previous findings. The major adverse effect observed was infection, which occurred during the first several cycles. Others were less toxic, especially the absence of grade 3/4 toxicities for hematological adverse effects.Although a dose reduction in lenalidomide therapy for elderly patients is controversial, a very low dose could be safe and effective. Our group is currently conducting a multi-center prospective trial to evaluate the efficacy of low-dose lenalidomide therapy.

AB - Lenalidomide treatment for refractory or relapsed multiple myeloma in elderly patients may be feasible in an outpatient setting. However, difficulties have been associated with the management of adverse effects. Therefore, a dose reduction in lenalidomide has been recommended in some cases. In this report, we encountered the successful treatment of myeloma in 6 elderly patients (aged above 70 years) with very low-dose lenalidomide (5 mg daily). Four patients exhibited more than a partial response with an 8.6 months median follow-up period, which was comparable with previous findings. The major adverse effect observed was infection, which occurred during the first several cycles. Others were less toxic, especially the absence of grade 3/4 toxicities for hematological adverse effects.Although a dose reduction in lenalidomide therapy for elderly patients is controversial, a very low dose could be safe and effective. Our group is currently conducting a multi-center prospective trial to evaluate the efficacy of low-dose lenalidomide therapy.

UR - http://www.scopus.com/inward/record.url?scp=84893110346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893110346&partnerID=8YFLogxK

M3 - Article

C2 - 23727684

AN - SCOPUS:84893110346

VL - 54

SP - 457

EP - 462

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 5

ER -